Lucas Nivon

Lucas Nivon is a prominent figure leading the Cyrus team, focused on discovering new drugs through algorithmic approaches. With a background in computational biophysics, Lucas is passionate about leveraging powerful computation to revolutionize the Biotechnology and Pharmaceutical industries. He co-founded Cyrus in 2015 as a spin-off from the University of Washington, where the team collaborates with industry partners, academia, and CROs to develop innovative protein-based drugs addressing critical medical needs.

Cyrus boasts a diverse client base including top Pharma, Biotech, Synthetic Biology, Chemicals, and Consumer Products companies, with collaborations spanning across the Americas, EU, China, and Japan. Notable partners of Cyrus include Janssen, BASF, Illumina, and Harvard Medical School, among others. In terms of funding, Cyrus has secured over $12M from key investors in the tech and biotech sectors, such as Trinity, SpringRock, Orbimed, Alexandria Venture Investments, W Fund, and WINGS.

Lucas Nivon's professional interests range from research strategy, business planning, product development, and market research to technical sales, computational biophysics, startup ventures, scientific coding, and team building. He is dedicated to applying cutting-edge scientific tools to create novel drugs, diagnostics, and biotechnological solutions for research, materials, and energy sectors. In addition to his work in biotechnology, Lucas previously co-founded PedalAnywhere, a company in the transportation industry, showcasing his entrepreneurial spirit and diverse skill set.

In terms of education, Lucas pursued his AB in Biochemistry and later a PhD in Biophysics at Harvard University, where he excelled academically. Additionally, he has been involved in various academic and professional roles, including serving as a Translational Investigator at the University of Washington, a Post-Doctoral Fellow at the University of Washington, and holding positions at Harvard University and ETH Zurich.

Lucas Nivon continues to drive innovation in the biopharmaceutical space by combining his expertise in computational biophysics with a passion for creating impactful solutions through advanced scientific algorithms and technology.